Contributors to newly developed coronary artery disease in patients with a previous history of percutaneous coronary intervention beyond the early phase of restenosis

Internal Medicine

Volumn 53, Issue 8, 2014, Pages 819-828

  Endo, Akihiro ^a   Yoshida, Yasuyuki ^b   Kageshima, Kenji ^b   Sato, Hirotomo ^a   Suga, Toshimitsu ^b   Nasu, Hiroshi ^b   Takahashi, Nobuyuki ^a   Tanabe, Kazuaki ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b TOTTORI PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Contributor; Revascularization; Risk factors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; BLOOD; COMORBIDITY; HEALTH BEHAVIOR; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COMORBIDITY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; FEMALE; HEALTH BEHAVIOR; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTORS;

EID: 84898661832     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.53.1438     Document Type: Article

References (22)

1. Kimura T, Yokoi H, Nakagawa Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med 334: 561-566, 1996.
2. Kimura T, Abe K, Shizuta S, et al. Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation 105: 2986-2991, 2002.
3. Fujii N, Asano R, Nagayama M, et al. Coronary stent implantation in patients with coronary artery disease-observational study over a decade-. Circ J 71: 1360-1365, 2007.
4. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare metal and drug-eluting stents. J Am Coll Cardiol 57: 1314-1322, 2011.
5. Takano M, Yamamoto M, Inami S, et al. Appearance of lipidladen intima and neovascularization after implantation of baremetal stents extended late-phase observation by intracoronary optical coherence tomography. J Am Coll Cardiol 55: 26-32, 2010.
6. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389, 1994.
7. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomized controlled trial. Lancet 368: 1155-1163, 2006.
8. Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 110: 1061-1068, 2004.
9. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very highintensity statin therapy on regression of coronary atherosclerosis: The ASTEROID Trial. JAMA 295: 1556-1565, 2006.
10. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297: 499-508, 2007.
11. Packard CJ, Ford I, Robertson M, et al. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 112: 3058-3065, 2005.
12. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment. Circulation 85: 37-45, 1992.
13. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425-1435, 2005.
14. Bayturan O, Kapadia S, Nicholls SJ, et al. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol 55: 2736-2742, 2010.
15. Grundy SM, Cleeman JI, Merz CN, et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44: 720-732, 2004.
16. von Birgelen C, Hartmann M, Mintz GS, Baumgart D, Schmermund A, Erbel R. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (> or =12 months) follow-up intravascular ultrasound. Circulation 108: 2757-2762, 2003.
17. Matsumoto I, Miyake Y, Mizukawa M, Takagi Y. Impact of lowdensity lipoprotein cholesterol/high-density lipoprotein cholesterol ratio on long-term outcome in patients undergoing percutaneous coronary intervention. Circ J 75: 905-910, 2011.
18. Japan Atherosclerosis Society guidelines for diagnosis and treatment of atherosclerotic cardiovascular diseases. Japan Atherosclerosis Society, Tokyo, 2012.
19. Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care 28: 2901-2907, 2005.
20. Weintraub WS, Pederson JP. Atherosclerosis and restenosis: reflections on the Lovastatin Restenosis Trial and Scandinavian Simvastatin Survival Study. Am J Cardiol 78: 1036-1038, 1996.
21. Inoue K, Abe K, Ando K, et al. Pathological analyses of longterm intracoronary Palmaz-Schatz stenting; Is its efficacy permanent? Cardiovasc Pathol 13: 109-115, 2004.
22. Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 25: 951-958, 2007.